1. New Zealand Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals Ltd.

4.64
NZD
+0.05
(+1.09%)
0.13EPS
23.92P/E
352.35MMarket Cap
Nov 19Next Earn
AFT Pharmaceuticals Ltd.
NZX:AFT
(New Zealand Exchange)

Recent

price

4.64

P/E

ratio

23.92

div

yld

0.39%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
NZD
2.32
0.71
0.82
0.87
1.09
1.09
1.24
1.49
1.85
1.96
2.4
Revenue per Share
-0.48
-0.19
-0.14
-0.02
0.13
0.08
0.19
0.1
0.15
0.11
0.14
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
0.06
- -
- -
- -
0.01
- -
- -
- -
0.01
0.02
0.02
Dividend per Share
0.29
0.11
-0.02
0.05
0.18
0.35
0.54
0.7
0.84
0.93
1.05
Book Value per Share
0.27
0.08
-0.07
-0.03
-0.1
0.04
0.18
0.26
0.33
0.38
0.44
Tangible Book Value per Share
28
97
97
97
97
103
105
105
105
105
105
Basic Weighted Avg Shares
64
69
80
85
106
113
130
156
194
205
251
Sales/Revenue/Turnover
-21.62
-25.1
-14.28
4.79
9.65
7.94
14.36
10.99
10.47
5.69
6.86
Operating Margin (%)
- -
- -
- -
- -
1
1
1
2
2
3
4
Depreciation Expense
-13
-18
-13
-2
13
8
20
11
16
12
15
Net Income, GAAP
- -
- -
- -
- -
1.44
1.33
- -
32.57
29.11
28.9
35.64
Effective Tax Rate (%)
-20.73
-26.57
-15.93
-2.85
12.02
6.88
15.29
6.84
8.04
5.82
5.86
Profit Margin (%)
48
39
30
-7
30
36
48
55
60
65
82
Working Capital
23
23
31
- -
45
36
36
35
31
28
42
LT Debt
28
19
7
5
17
37
57
73
88
97
109
Total Equity
- -
- -
- -
- -
18
12.36
- -
10.98
12.21
6.56
7.4
Return on Invested Capital (%)
- -
- -
- -
- -
37.07
15.6
- -
11.92
15.57
11.6
11.58
Return on Capital (%)
- -
-95.33
- -
- -
113.6
28.91
42.53
16.39
19.38
12.9
14.17
Return on Common Equity (%)

Capital Structure

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

NZD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
35.4%
25.39%
12.35%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-57.98%
31%
23.14%
Sales/Revenue/Turnover
14.87%
17.49%
22.24%
Total Cash Common Dividend
- -
- -
12.46%

Semi-annual Revenue

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
194
2025
- -
- -
205
2026
- -
- -
251

Semi-annual Earnings Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.15
2025
- -
- -
0.11
2026
- -
- -
0.14

Semi-annual Dividends Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.01
2025
- -
- -
0.02
2026
- -
- -
0.02
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
AFT Pharmaceuticals Limited is a New Zealand-based pharmaceutical company specializing in the development, manufacturing, and marketing of proprietary pharmaceutical products and consumer healthcare products. The company's core offerings include prescription medicines; over-the-counter (OTC) pharmaceuticals; complementary and wellness products; and specialty pharmaceutical products primarily targeting respiratory, dermatological, gastrointestinal, and musculoskeletal conditions. AFT markets a diverse portfolio of branded and generic medicines, including nasal sprays, eye drops, analgesics, cough and cold remedies, and vitamins and supplements. Founded in 1976 and headquartered in Auckland, New Zealand, AFT Pharmaceuticals operates globally with commercial presence in Australia, New Zealand, the United States, the United Kingdom, and several other international markets. The company serves healthcare professionals, pharmacies, hospitals, and consumers in these regions. In the past 1-2 years, AFT Pharmaceuticals has focused on strategic growth initiatives, including expanding its product pipeline with new launches, forming strategic partnerships to enhance market reach, and acquiring complementary product lines to diversify its portfolio. Notably, the company has strengthened its respiratory and dermatology segments, launched innovative consumer health products, and extended its distribution capabilities in key international markets. These developments reflect AFT's commitment to broadening its therapeutic offerings and enhancing its global footprint in the pharmaceutical sector. Overall, AFT Pharmaceuticals Limited positions itself as a specialist healthcare company delivering clinically effective medicines and wellness products with a growing international presence. Its blend of proprietary innovations and established brands supports sustained growth within the pharmaceutical and consumer healthcare industries.

Company News

Company News APIChatGPT

  • globenewswire.com

    Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market